Compare iShares MSCI Japan ETF (EWJ) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Japan ETF vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? iShares MSCI Japan ETF trades at $94.51 (market cap $23.22B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.65 (market cap $977.37M). The key difference: iShares MSCI Japan ETF is far larger — about 23.8× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and iShares MSCI Japan ETF is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Japan ETF for 57 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| EWJ | MRVI | |
|---|---|---|
Market Cap | $23.22B | $977.37M |
Volume | 5,587,717 | 2,742,564 |
Sector | Broad Market / Factor | Health |
52-Week High | $99.32 | $9.00 |
52-Week Low | $79.49 | $2.83 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | — | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWJ, a US-listed ETF tracking Japanese equities, trades at $97.32 with no change on the day. Technical indicators show a bullish overall signal, with moving averages supporting an uptrend while oscillators remain neutral. Recent news highlights Japan's monetary policy shifts and international ETF outperformance, with the Nikkei 225 experiencing volatility amid rising bond yields and fiscal stimulus debates.
The outlook for EWJ is cautiously optimistic, driven by Japan's economic stimulus and potential yen strength, but risks include BOJ policy uncertainty and global yield pressures. Investors may find opportunity in Japan's AI and semiconductor exposure, though currency fluctuations and fiscal challenges pose headwinds for sustained gains.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Japan ETF
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
